¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"focus assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁý°Ë»ç
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤(¹ý), ¿ëÇ÷ÇöóÅ©ÃøÁ¤(¹ý)
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤(¹ý), ¸é¿ªÇü±¤°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    Ãʰú»êÈ­¹°ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁýÃøÁ¤(¹ý)
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ©ÃøÁ¤¹ý
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Raji cell assay
    ¶óÁö¼¼Æ÷½ÃÇè
  • SPA => spermatozoa penetration assay
    Á¤ÀÚ°üÅë½ÃÇè
  • TCD50 assay
    50%Á¾¾çÁ¶Àý¾ç
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • acid phosphatase assay
    »ê¼ºÆ÷½ºÆÄŸÁ¦ ÃøÁ¤
  • ames assay
    ¿¡ÀÓ½ººÐ¼®
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigenic assay
    Ç׿ø¼ººÐ¼®
  • antimicobial assay
    Ç×±ÕÁ¦ÃøÁ¤
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • hemizona assay (index)
    ¹ÝÅõ¸í´ë ÃøÁ¤(ÁöÇ¥)
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • immunoconcentration assay
    ¸é¿ª³óÃàÃøÁ¤<--Á¤·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • focus, immunofluorescence
    ¸é¿ªÇü±¤ Áß½É
  • front focus
    ÀüÃøÃÊÁ¡.
  • ghon focus
    °ï º´¼Ò, Ghon º´¼Ò
  • infection focus
    °¨¿°¼Ò(Êïæøáµ).
  • internal focus
    ³»ºÎ ÃÊÁ¡
  • primary focus
    ¿ø¹ß¼Ò(ê«Û¡áµ).
  • primary focus
    ¿øº´¼Ò
  • principal focus
    ÁÖÃÊÁ¡(ñ«õ¥ïÇ).
  • sensate focus exercises
    °¨°¢ÁýÁßÈÆ·Ã
  • unilateral focus
    ÀÏÃø¼º(ìéö°àõ)ÃÊÁ¡.
  • visual focus
    ½Ã°¢ÃÊÁ¡(¡­õ¥ïÇ).
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • acid phosphatase assay
    »ê¼ºÆ÷½ºÆÄŸÁ¦ ÃøÁ¤
  • ames assay
    ¿¡ÀÓ½ººÐ¼®
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunofluorometric assay
    ¸é¿ªÇü±¤ÃøÁ¤(Øóæ¹û«ÎÃö´ïÒ) ¾Æ½êÀÌ
  • immunoradiometric assay
    ¸é¿ª¹æ»ç´ÉÃøÁ¤(Øóæ¹Û¯ÞÒÒöö´ïÒ) ¾Æ½êÀÌ
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
  • kinetic assay
    ¿ªµ¿(æ³ÔÑ)¾Æ½êÀÌ
  • linked assay
    ¿¬°è(ææÍ¨)¾Æ¼¼ÀÌ
  • linked enzyme assay procedure
    ¿¬°èÈ¿¼Ò(ææÍ¨ý£áÈ) ¾Æ½êÀÌ ¹æ½Ä(Û°ãÒ)
  • microbiological assay
    ¹Ì»ý¹°(Ú°ßæÚª)¾Æ¼¼ÀÌ
  • plaque assay
    ÇöóÅ© ¾Æ½êÀÌ
  • radioisotopic enzyme assay
    ¹æ»ç¼º µ¿À§¿ø¼Ò È¿¼Ò(Û¯ÞÒàõÔÒêÈêªáÈý£áÈ) ¾Æ½êÀÌ
  • rat antidiuresis assay
    Áã Ç×ÀÌ´¢(ù÷××Òã) ¾Æ½êÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
EFFU epithelial focus-forming unit
FFD Fellow in the Faculty of Dentistry; focus-film distance
FFIT fluorescent focus inhibition test
FOD focus-to-object distance; free of disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
C focus
FFU focus forming units
MCF mink cell focus forming
SFFVP spleen focus-forming virus
SPRIA Solid Phase Radioimmune Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antimicobial assay
    Ç×±ÕÁ¦ ÃøÁ¤
  • assay
    Á¤·®, ¿ª°¡ °ËÁ¤, È¿·Â °ËÁ¤
    È¥ÇÕ¹°¿¡ ÀÖ´Â ¼ººÐÀÇ ¾ç, ¶Ç´Â ¾à¹°ÀÇ »ý¹°ÇÐÀû, ¾à¸®ÇÐÀû ¿ª°¡ µîÀÇ ÃøÁ¤.
  • calcitonin assay
    Ä®½ÃÅä´Ñ ÃøÁ¤
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • carcinogen assay
    ¹ß¾Ï ¹°Áú °Ë»ç
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • colony formation assay
    Áý¶ô Çü¼º´É ÃøÁ¤
  • enzymatic assay
    È¿¼Ò¼º ÃøÁ¤, È¿¼Ò¼º ÃøÁ¤¹ý
  • enzyme-linked immunoadsorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ½ÃÇè, ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷ Á¤ÀÚ Åõ¸í´ë ºÎÂø °Ë»ç
  • microbiological assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • micrologica assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • radioreceptor assay
    ¹æ»ç¼± ¼ö¿ëü ÃøÁ¤¹ý
    ÀÏÁ¾ÀÇ ¹æ»ç Ç¥Áö °ËÁ¤¹ýÀ¸·Î¼­, Á¶Á÷ Ç¥º» ³»¿¡ Àִ ȣ¸£¸ó¿¡ ´ëÇØ Ư¼öÇÑ ¼¼Æ÷ ¼ö¿ëüÀÇ ³óµµ¸¦ ¹æ»ç Ç¥ÁöÇÑ È£¸£¸óÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Friend spleen focus forming virus <virology> Defective virus found in certain strains of Friend virus, detected by its ability to form foci in spleens of mice and believed to be responsible in those strains for the production of a leukaemia associated with polycythaemia rather than anaemia.
(18 Nov 1997)
acetyl reduction assay <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase.
(06 May 1997)
Ames assay <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria.
(18 Nov 1997)
antibiotic assay <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical.
(09 Oct 1997)
assay <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug.
(10 May 1997)
bandshift assay <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences.
A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound.
(18 Nov 1997)
biological assay <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity.
It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein.
(21 Mar 1998)
radioimmunoprecipitation assay Sensitive assay using radiolabelled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as protein a sepharose beads. The bound radiolabelled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (ripa) is often used as a confirmatory test for diagnosing the presence of HIV antibodies.
(12 Dec 1998)
radioligand assay <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
(12 Dec 1998)
radioreceptor assay A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody.
(05 Mar 2000)
Raji cell radioimmune assay For immune complexes; a procedure by which immune complexes adsorbed from a test serum by a standard preparation of lymphoblastoid (Raji) cells are assayed by the capacity to bind 125I-labelled antibody to immunoglobulin.
(05 Mar 2000)
gel retardation assay A lab technique used to find out if there are proteins binding a fragment of DNA (in a DNA-protein complex) by watching how fast the DNA fragment moves through an electric field and seeing whether it moves slower when a particular protein is also present.
(09 Oct 1997)
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
Grunstein-Hogness assay A procedure for identifying plasmid clones by colony hybridization.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á